Geographic Atrophy

Geographic Atrophy is a type of dry macular degeneration. This is a condition that affects the central part of your eye, called the macula. It causes a specific area to become damaged or thin over time, leading to vision problems.

Condition

What people with Geographic Atrophy report

Every report comes from a Lived member, sent anonymously.

Have you tried Lutein for Geographic Atrophy?

NameHow it went

About Geographic Atrophy

What It Is

Geographic atrophy (GA) is the advanced stage of dry age-related macular degeneration (AMD). The macula is the small central part of the retina, the light-sensitive layer at the back of the eye, and it provides the sharp, straight-ahead vision used for reading, recognizing faces and driving. In GA, patches of macular cells waste away and stop working. Each patch becomes a blind spot, and the patches slowly grow and merge over the years. The damage usually begins just beside the very center of vision, so some people can still read an eye chart reasonably well while finding print, faces and dim lighting increasingly hard. Once the atrophy reaches the center, sharp vision drops more noticeably. GA does not cause total blindness, because side vision is preserved, and it usually affects both eyes, though not always at the same pace. GA is different from wet AMD, the other late form of the disease, in which abnormal blood vessels leak under the macula and vision can worsen quickly. The two can occur together, and an eye with GA can later develop wet AMD. Earlier stages of dry AMD, with yellow deposits called drusen but no atrophy, are not geographic atrophy.

Causes & Risk Factors

Age is the strongest risk factor, and most people with GA are over 60. A family history of AMD raises risk, and so does smoking, for both current and former smokers. GA is more common in people of European ancestry. Inherited differences in the complement system, part of the immune system that responds to injury and infection, are strongly linked to AMD and GA. That link is why the newest treatments work by calming complement activity in the eye. Most people with GA first had earlier dry AMD for years, and having late AMD in one eye raises the chance of developing it in the other. These are risk factors, not personal failings, and having them does not mean GA is certain.

How It's Diagnosed

GA is diagnosed by an eye doctor, usually an ophthalmologist or retina specialist, during a dilated eye exam. Drops widen the pupil so the doctor can see the macula and recognize the sharply outlined pale areas where tissue has been lost. There is no blood test for GA. Imaging confirms the diagnosis and sets a baseline. Fundus autofluorescence photographs the natural glow of healthy cells beneath the retina; areas that have died appear dark, which lets the doctor measure the size of the atrophy and track how fast it grows. Optical coherence tomography (OCT) is a painless scan that shows the retina's layers in cross section, confirms which layers are lost, and checks for fluid that would signal wet AMD. A standard eye chart can understate the problem when the very center is spared, so the doctor may also ask about reading, night vision and blind spots, and sometimes test vision in low light or map sensitivity across the macula. In younger people, or when the pattern is unusual, inherited retinal conditions such as Stargardt disease can look similar and may need to be ruled out.

Treatment Options

There is no treatment that reverses GA or restores vision that has been lost, but two medicines can slow how fast the atrophy spreads. Pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) were approved by the US Food and Drug Administration in 2023. Both are complement inhibitors that are injected into the eye after the surface is numbed: Syfovre every one to two months and Izervay about monthly, continuing for as long as treatment is kept up. In clinical trials these injections slowed the growth of GA by roughly 14% to 22% over one to two years compared with sham treatment. That means the damaged area still grew, only somewhat more slowly. Neither medicine has been shown to improve eyesight or reading, so the possible benefit is preserving vision over the longer term. The trade-offs are frequent visits, the discomfort and cost of ongoing injections, and side effects. Both raised the chance of developing wet AMD (for example, 12% of people on monthly Syfovre over two years versus 3% without it), which then needs its own injections. Any eye injection carries a small risk of serious infection inside the eye or retinal detachment. Syfovre has also been linked to rare inflammation of the retinal blood vessels, sometimes after the first dose, that can cause severe vision loss. Whether to start, and how often to treat, is a decision to weigh with a retina specialist. The vitamin and mineral formula tested in the Age-Related Eye Disease Study 2 (AREDS2) does not slow GA itself. It is used for intermediate AMD and, when late AMD affects only one eye, may help protect the other eye. Laser treatment and injections that block vascular endothelial growth factor (VEGF), a protein that drives leaky vessel growth, are treatments for wet AMD, not for GA, though anti-VEGF injections are used if wet AMD develops. Not smoking is worthwhile at any stage. Low vision rehabilitation is often the most practically helpful care. Specialists can recommend magnifiers and other low vision devices, better lighting, and new ways to read and handle daily tasks, and this can help even while eye chart vision still looks fairly good.

What to Expect

GA usually progresses slowly, over years rather than weeks, but the pace varies widely between people and between a person's two eyes. Vision lost to GA does not come back. Many people first notice that reading takes longer, that they need much brighter light, that adjusting to dim rooms is slow, or that parts of words or faces seem to be missing. When the center of the macula becomes involved, fine detail becomes much harder to see. Because side vision remains, most people can keep moving around familiar places independently. Over time, tasks that depend on central vision, such as reading small print, recognizing people across a room and driving, may become difficult or unsafe, and it helps to discuss driving with the eye doctor before it becomes a crisis. Follow-up visits with imaging track how quickly the atrophy is growing and watch for wet AMD in either eye. People who choose injections have visits every one to two months; vision is often blurry for a short time afterward, so arranging a ride home is wise. Low vision services, adapted routines and support from family or patient organizations can make daily life more manageable as needs change.

When to Seek Help

See an eye doctor for a dilated exam if reading or seeing in dim light is getting harder, if you notice gaps or blurry patches in your central vision, or if you are over 55 with a family history of AMD and have not had a recent exam. People with GA should keep regular follow-up appointments, and ask for a low vision referral when daily tasks become difficult. Contact your eye doctor right away if straight lines start to look wavy or crooked, or if a blurry or blank area in your vision appears or grows quickly. These changes can mean wet AMD, which has treatments that work best when started early. If you receive Syfovre or Izervay injections, call your ophthalmologist immediately for same-day care if the treated eye becomes red or painful, becomes sensitive to light, or if your vision changes in the days after an injection, including new flashes of light, floaters, blurring or distortion. These can be signs of infection, inflammation or retinal detachment.

Questions to Ask Your Doctor

  1. 1.How close is the atrophy to the center of my vision in each eye, and how fast has it been growing?
  2. 2.Would Syfovre or Izervay make sense for me, and how would we judge whether the benefit is worth the injections and the risks?
  3. 3.How will we watch for wet AMD, and what changes at home should prompt me to call?
  4. 4.Should I take AREDS2 supplements to protect my other eye?
  5. 5.Can you refer me to low vision rehabilitation, and how should I think about driving now and in the future?

Last reviewed • Oct 2026

Educational content, not medical advice.